Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Humpert, P. M.
Right arrow Articles by Bierhaus, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Humpert, P. M.
Right arrow Articles by Bierhaus, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:934-936, 2005
© 2005 by the American Diabetes Association, Inc.

Pathophysiology/Complications
Brief Report

SDF-1 Genotype Influences Insulin-Dependent Mobilization of Adult Progenitor Cells in Type 2 Diabetes

Per M. Humpert, MD, Renate Neuwirth, Marco J. Battista, Olga Voronko, MD, Maximilian von Eynatten, MD, Ilze Konrade, MD, Gottfried Rudofsky, Jr, MD, Thoralf Wendt, MD, Andreas Hamann, MD, Michael Morcos, MD, Peter P. Nawroth, MD and Angelika Bierhaus, PHD

From the Department of Medicine I, University Clinics Heidelberg, Heidelberg, Germany

Address correspondence and reprint requests to Dr. Angelika Bierhaus, PHD, Medizinische Klinik 1, University of Heidelberg, INF 410, 69120 Heidelberg, Germany. E-mail: angelika.bierhaus{at}med.uni-heidelberg.de

Abbreviations: pBMC, peripheral mononuclear cell • PC, progenitor cell


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
CD34+/CD133+ circulating adult progenitor cells (PCs) play an important role in tissue repair in metabolic disease. PCs have a certain plasticity to differentiate into cells with tissue-specific phenotypes (1–3). In diabetic mice, therapeutic use of PCs in models of hindlimb ischemia and wound healing was particularly effective, suggesting a diabetes-dependent defect in PC function (4,5). Accordingly, in vitro outgrowth and angiogenic function of endothelial PCs differentiating from PCs (1) is diminished in patients with cardiovascular risk factors and in type 1 and type 2 diabetes (6–8). From clinical studies it is evident that insulin therapy is a factor determining cardiovascular complications and mortality in diabetes (9,10). It can therefore be speculated that insulin might influence mobilization of PCs in type 2 diabetes. In view of the strong genetic background for the development of late diabetes complications, we asked whether the SDF1-3'A/G genotype known to enhance PC mobilization (11) might be of influence.


   RESEARCH DESIGN AND METHODS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
In the pilot study presented here, we quantified the number of PCs by flourescence-activated cell sorter (FACS) analysis in 23 patients with poorly controlled type 2 diabetes (HbA1c 10.6 ± 1.6%, fasting glucose 15.9 ± 4.5 mmol/l) and 10 age-matched control subjects (59 ± 14 vs. 58 ± 10 years) without history of diabetes (HbA1c 5.4 ± 0.5%). After 5.4 ± 1.6 weeks of treatment with (additional) insulin, 11 patients from this cohort had a follow-up measurement of PCs. Adequate insulin supplementation was documented by a lowering of HbA1c of 1.5 ± 0.7%. All patients gave written consent, and the study was approved by the local ethics committee. All factors known to influence or possibly influencing the number of circulating PCs were excluded (i.e., infection, abnormal blood count, ischemia, anemia, hypoxia, statin [12] or erythropoietin [13] therapy, chemotherapy, immunosuppression). All patients who attended the follow-up examination were treated with insulin (7 of 11 on an intensified regimen); 5 received metformin and only 1 was treated with sulfonylurea.

FACS analysis and genotyping
Venous blood (30 ml) was drawn for detection of PCs and genotyping. Peripheral mononuclear cells (pBMCs) were isolated by density gradient centrifugation and incubated with anti–CD34-FITC (fluorescein isothiocyanate), anti–CD133-PE (phycoerythrin) (Miltenyi Biotech), and isotype controls (Becton Dickinson). The FACS analysis was normalized by single and double staining using isotype controls for each patient and measurement. PCs were counted and analyzed using FACS Calibur cell sorter (Becton Dickinson) and Cell Quest Pro Software (Becton Dickinson). SDF1 genotype was detected by PCR and restriction analysis as previously described in detail (14).

Statistical analysis
Student’s t test, paired Student’s t test, Pearson’s correlation, and multivariate analysis were used for statistical validation (SPSS software). All data are given as means ± SD.


   RESULTS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
Numbers of circulating CD34+/133+ cells (Fig. 1A) did not differ significantly between age-matched control subjects and patients with type 2 diabetes (0.071 ± 0.033 vs. 0.061 ± 0.035% of pBMC, P = 0.48). PCs did not correlate with micro- or macrovascular late complications in this small cohort with a diabetes duration of 9 ± 9 years (not shown). For methodological evaluation, numbers of PCs were detected in two healthy volunteers and four serial measurements over a period of 2 months, revealing a SD of 12% (not shown). After a medium time of 5.4 ± 1.6 weeks and adequate insulin supplementation, PCs increased in all 11 patients of the initial cohort attending the follow-up examination by 65.6 ± 62.7% (P = 0.007) (Fig. 1B). During this time, mean HbA1c fell significantly from 10.2 ± 1.4 to 8.7 ± 0.6% (P < 0.001). Yet, neither fasting glucose levels in the initial cohort (n = 23, R = 0.14) (Fig. 1C) nor improvement of long-term glucose control as measured by change in HbA1c (R = 0.03) (not shown) correlated with PC numbers or mobilization. However, the individual PC mobilization varied from 8% to a 176% increase and prompted us to screen the cohort for the SDF1-3'A/G genotype. Initial numbers of PCs in the cohort did not differ significantly between SDF-1 genotypes (0.08 vs. 0.05%, P = 0.16) (not shown). Although the effectiveness of insulin therapy was similar in both groups (decrease of HbA1c 1.5 ± 1.0 vs. 1.4 ± 0.4%, P = 0.8), carriers of the SDF1-3'A/G allele presented with a significantly enhanced mobilization of PCs compared with carriers of the SDF1-3'G/G allele (103.5 ± 48.4 vs. 23.6 ± 23.7%, P = 0.02) (Fig. 1D). Multivariate analysis for age, sex, change in HbA1c, BMI, and SDF1 genotype in this small cohort identified the SDF1-3'A/G variant to be the only independent predictor of PC mobilization upon insulin therapy (P = 0.027).



View larger version (33K):
[in this window]
[in a new window]
  		Figure 1— A: FACS analysis. Double staining of CD34 and CD133 antigens on pBMCs. Fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-coupled isotype controls were used for normalization. CD34+/133+ adult PCs are shown in the upper right quadrant. B: Number of PCs (% of pBMCs) in patients with poorly controlled type 2 diabetes before (gray bar) and after 5.4 weeks of insulin therapy (n = 11, black bar). (P value as given by paired t test for normally distributed values.) C: Correlation of CD34+/133+ in pBMCs (%) with fasting blood glucose (mmol/l). (R, Pearson’s correlation coefficient; P value as given for Pearson’s correlation.) D: Mobilization of CD34+/133+ cells in pBMCs (%) after 5.4 weeks of treatment with additional insulin for carriers of SDF1-3'G/G allele (gray bar) and carriers of SDF1-3'A/G allele (black bar). P value as given by Student’s t test.

 

   CONCLUSIONS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
The data presented in this pilot study have two major implications. First, this is the first study showing an effect of insulin therapy on mobilization of circulating CD34/133-positive pluripotent PCs in patients with type 2 diabetes. Second, the SDF1-3'A/G genotype leads to enhanced recruitment of PCs upon insulin therapy. Multivariate analysis revealed the SDF1-3'A/G variant to be an independent predictor of enhanced PC mobilization after adequate insulin supplementation. Consistent with this, it was just recently shown that SDF-1 regulates mobilization of PC (15). A change in SDF-1 expression in the SDF1-3'A/G genotype might thus enhance mobilization of PCs after insulin therapy.

Recruitment of suitable patients, excluding all factors known to influence PCs, was difficult; hence, the impact of this study is clearly limited due to small patient numbers. Nevertheless, the results obtained in the well-defined cohort that was followed up after insulin treatment are highly significant. It is beyond the scope of this pilot study to elucidate the molecular mechanisms by which insulin interacts with PC mobilization. However, influences of insulin on chemotaxis and inflammatory reactions (16–18), as well as proliferation of PCs (19), should be considered, and ongoing studies should aim to answer some of the questions addressed. This pilot study is not sufficient to rule out minor effects of hyperglycemia and oxidative stress on PC mobilization and demands for larger clinical trials to study the effects of different insulin preparations (insulin analogs) on PC mobilization and development of diabetes complications. This is especially true for diabetic retinopathy, since PCs seem to play a crucial role in the retinal neoangiogenesis and could possibly influence the progression of this complication (20).


   Acknowledgments
 
This work was in part supported by grants from the Deutsche Forschungsgemeinschaft (Na 138/5-3 to P.P.N.), the Lautenschläger Stiftung (to P.P.N. and A.B.), the European Foundation for the Study of Diabetes (Lilly Research Grant to A.B.), and the Deutsche Diabetes Gesellschaft (to P.M.H. and A.B.).


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication November 30, 2004. Accepted for publication December 20, 2004.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952–958, 2000[Abstract/Free Full Text]
  2. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z: Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108:2070–2073, 2003[Abstract/Free Full Text]
  3. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967, 1997[Abstract/Free Full Text]
  4. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 106:571–578, 2000[Medline]
  5. Sivan-Loukianova E, Awad OA, Stepanovic V, Bickenbach J, Schatteman GC: CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res 40:368–377, 2003[Medline]
  6. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593–600, 2003[Abstract/Free Full Text]
  7. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781–2786, 2002[Abstract/Free Full Text]
  8. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ: Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195–199, 2004[Abstract/Free Full Text]
  9. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515, 1997[Abstract/Free Full Text]
  10. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367, 2001[Abstract/Free Full Text]
  11. Benboubker L, Watier H, Carion A, Georget MT, Desbois I, Colombat P, Bardos P, Binet C, Domenech J: Association between the SDF1–3'A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol 113:247–250, 2001[Medline]
  12. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391–397, 2001[Medline]
  13. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340–1346, 2003[Abstract/Free Full Text]
  14. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O’Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O’Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279:389–393, 1998[Abstract/Free Full Text]
  15. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864, 2004[Medline]
  16. Yenush L, Kundra V, White MF, Zetter BR: Functional domains of the insulin receptor responsible for chemotactic signaling. J Biol Chem 269:100–104, 1994[Abstract/Free Full Text]
  17. Aljada A, Ghanim H, Saadeh R, Dandona P: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86:450–453, 2001[Abstract/Free Full Text]
  18. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257–3265, 2001[Abstract/Free Full Text]
  19. Miyagawa S, Kobayashi M, Konishi N, Sato T, Ueda K: Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol 109:555–562, 2000[Medline]
  20. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M: Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 8:1004–1010, 2002[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
G. P. Fadini, I. Baesso, C. Agostini, E. Cuccato, G. B. Nardelli, A. Lapolla, and A. Avogaro
Maternal Insulin Therapy Increases Fetal Endothelial Progenitor Cells During Diabetic Pregnancy
Diabetes Care, April 1, 2008; 31(4): 808 - 810.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
G. P. Fadini, S. Sartore, C. Agostini, and A. Avogaro
Significance of Endothelial Progenitor Cells in Subjects With Diabetes
Diabetes Care, May 1, 2007; 30(5): 1305 - 1313.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. C. Schatteman, M. Dunnwald, and C. Jiao
Biology of bone marrow-derived endothelial cell precursors
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. M. Humpert, M. J. Battista, A. Lammert, P. Reismann, Z. Djuric, G. Rudofsky Jr, M. Zorn, M. Morcos, H.-P. Hammes, P. P. Nawroth, et al.
Association of stromal cell-derived factor 1 genotype with diabetic foot syndrome and macrovascular disease in patients with type 2 diabetes.
Clin. Chem., June 1, 2006; 52(6): 1206 - 1208.
[Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Humpert, P. M.
Right arrow Articles by Bierhaus, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Humpert, P. M.
Right arrow Articles by Bierhaus, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum